Laura Janocko, PhD

Laura was diagnosed with stage 4 lobular breast cancer in 2012.  While initial treatments included mastectomy, radiation and anti-hormonal therapy, she has done expremely well on targeted therapy with an mTOR inhibitor for the past two years.  She was employed as a molecular biologist performing HIV research until September 2015, when her position was downsized; she is actively seking another position.  Laura is a member of the Breast Cancer Research Advocacy Network (bcRAN) and recently agreed to serve as a patient advocate on a research grant.  This is her first TRCCC meeting.